Leadership

Management
team

LNC’s management team is deeply inspired by companies that have been able to transform scientific discoveries into innovative pharmaceutical products thanks to their strong vision and successful strategy.

LNC - Georges Dr.  Rawadi (PhD, MSc), CEO
Passionate about innovation

Dr. Georges Rawadi (PhD, MSc)

A former researcher at the Institut Pasteur, Georges was Vice-President of Business Development & Intellectual Property and a member of the management team at Celyad.

He previously served in various business development roles at Cellectis, Galapagos, ProStrakan and Sanofi-Aventis and led strategic alliance development consulting assignments.

He holds a PhD in Microbiology from Pierre and Marie Curie University (France) and a master’s degree in Management and Strategy in the Health Industry from ESSEC Business School.

LNC - Sandrine Dr. Sandrine Claus (PhD, MRSB), CSO
Beyond state of the art

Dr. Sandrine Claus (PhD, MRSB)

Sandrine joined LNC Therapeutics in 2017 as Chief Scientific Officer. She previously served as Associate Professor in Integrative Metabolism at the University of Reading’s department of Food and Nutritional Sciences.

Her research focused on host-gut microbial metabolic interactions in order to link gut microbial ecology to metabolic health.

A scientist at heart, Sandrine founded her own laboratory at the age of 27, after obtaining her PhD in Biochemistry at Imperial College London, where she started to study host-gut microbiota metabolic interactions.

LNC - Fabrice Fabrice Guez, co-founder & CFO
Putting people first

Fabrice Guez, co-founder of LNC Therapeutics

An experienced CFO, Fabrice decided to switch gears after gaining extensive experience as a financial auditor, getting involved in operations at a number of pharmaceutical SMEs, where he successfully headed up change management processes, thanks to his flexibility and excellent people skills.

Fabrice co-founded LNC Therapeutics in 2010, firmly convinced by its innovative approach and keen to take on an entrepreneurial challenge.

Board of
directors

Real “sparring partner” for LNC’s management team, our board is gathering Biotech & Life Sciences specialists.

LNC - Jean-Luc  Treillou, co-founder & Chairman

Jean-Luc Treillou, president LNC Therapeutics

With a Doctorate of Pharmacy and a qualification from a business school, Jean-Luc started his career in 1995 with SmithKline-Beecham (subsequently GSK) before joining Aventis Pharma (subsequently Sanofi) to work in a variety of industrial and financial roles based in Europe, Asia and Africa (Vietnam, Senegal, Maroc).

more +

Fascinated by the field of nutrition, and convinced of its added value in the global management of patients, for the past ten years Jean-Luc has been focusing on the convergence between nutrition and pharmaceuticals in the context of the changing business model for the life sciences, and has been the manager or director of several SME.

He has also acted as a consultant for European investment funds, pharmaceutical companies and firms specialised in medical nutrition.

LNC - Isabelle  de Crémoux, president & CEO Seventure Partners

Isabelle de Crémoux, president & CEO Seventure Partners

Isabelle brings 25 years of international experience in life sciences business development and finance. She started her career in ’91 at Arthur Andersen Detroit, US then at Pfizer France and Pfizer Europe where she held several positions during 6 years in the field of management accounting, clinical research then Business Development.

more +

Since ’98, she was Associate Director of Business Development at Fournier/Abbott and signed several deals in Europe and in the US. Isabelle graduated as an engineer from Ecole Centrale of Paris and holds DECF and ISEB degrees and joined Seventure in July 2001 to create the lifesciences department.

Isabelle leads the lifesciences team and makes direct investments, mainly in France and Scandinvia with a focus on biotech, nutrition, personalized medicine and especially microbiome. Isabelle’s trackrecord includes Santaris (solde to Roche for $450 millions in august 2014), argenx (listed), OPI pharma (sold to Eusa for Euro 110 millions), Bioalliance (listed), Pixium Vision (listed), as well as Enterome Bioscience.

LNC - Mathieu  Simon, MD

Mathieu Simon, MD

Mathieu is today Senior Advisor at Messier Maris & Associés an advisory M&A firm located in Paris, New York and London. In addition to this role, Mathieu Simon is a Venture partner at B/B biotec Pureos Bioventures (Bellevue Venture Capital) in Zurich, CH.

more +

Dr Simon is also an independent director at the Board of Vaximm AG (CH ), and member of Affimed supervisory board (AFMD NASDAQ ) and has been Chairman of the Board of Cellartis AB a pioneer in regenerative medicine in Sweden until 2014 before its acquisition by Takara Bio.

Mathieu SIMON, MD, has served also as Executive Vice-President, Chief Operating Officer of Cellectis since 2012 and as Member of the Board of Cellectis since 2014. Prior to this function Mathieu Simon was CEO of Cellectis Therapeutic and CEO of Ectycell from 2012 to 2014. Mathieu Simon as head of Cellectis Therapeutics with Andrew Scharenberg, MD (Seattle Children’s hospital) serving as CSO have been very instrumental in the development of Cellectis first in class allogenic CAR T cells targeting haematological malignancies now today in clinical development in the USA.

Prior to joining Cellectis, Dr SIMON was Managing Director, Head of Global Pharma at Pierre Fabre SA, the third largest French Pharma Company. Prior to this role, Dr Simon has worked 18 years at Wyeth Pharmaceuticals where he had several general management and regional roles in the EU region (10 years as President of Wyeth Italy) as swell as senior corporate functionsas Senior Vice President Head of Wyeth Global Marketing and Medical Affairs in Philadelphia, USA.

Dr Mathieu Simon is also advisor of the EU Commission (Horizon 2020 Programme)

LNC - Catherine  Combot-Pletan, Pharm D

Catherine Combot-Pletan, Pharm D

Catherine has more than 20 years of experience in Start-up, Biotech, Pharma, CRO and Consulting mainly in strategy and project management for R&D programs of innovative biologic drugs.

more +

Her career started by Clinical Research and she has been Head of the Clinical Department of Chiltern International for many years, with the responsibility of all clinical trials in several countries.

Then she moved to the full drug development and has acquired an expertise in Global Operations, CMC, Regulatory & Translational project management of NBE’s early development with a global vision from Research all the way to Market Launch.

She successfully led products up until phase II POC through several positions notably as Strategic Project Director on blood factors and Mabs Programs in LFB Biotechnologies then as Head of Projects Development in Gamamabs Pharma where she had the responsibility of the global operations and has contributed to funds raising.

Since 2016, she is the President and Founder of ULTRace Development Partner whereby she advises biotechs and start-ups by creating value through strategic support, operations development and project management. She is also member of the management team for some of them.

LNC - Georges Dr.  Rawadi (PhD, MSc)

Dr. Georges Rawadi (PhD, MSc)

A former researcher at the Institut Pasteur, Georges was Vice-President of Business Development & Intellectual Property and a member of the management team at Celyad.

more +

He previously served in various business development roles at Cellectis, Galapagos, ProStrakan and Sanofi-Aventis and led strategic alliance development consulting assignments.

He holds a PhD in Microbiology from Pierre and Marie Curie University (France) and a master’s degree in Management and Strategy in the Health Industry from ESSEC Business School.

LNC - Virginie  Lleu, managing director L3S Partnership

Virginie Lleu, managing director L3S Partnership

Holding a Supplementary Specialised Studies Diploma (DESS) in Clinical Psychopathology, and bilingual in English, she started her professional career by gaining clinical experience in hospitals as a neuropsychologist.

more +

In 1992, Virginie Lleu joined the pharmaceutical company Jouveinal to work in its Human Resources Directorate. She then moved as a consultant to a recruitment agency specialised in the healthcare field, GSA, subsequently joining Pact & Partners International as Senior Consultant responsible for the Health and Biotechnologies sector.

As from 2000, Virginie pursued her work as a recruitment consultant with Executive Search International entities such as Korn Ferry International and Spencer Stuart, where she contributed to developing the Health and Biotechnologies Department.

After accomplishing a large number of missions in a variety of functions (general management, R&D, marketing/sales, manufacturing, business development, HR, finance, etc.), in 2003 Virginie founded L2S (Life Science Search), a recruitment consultancy based on direct contact and dedicated specifically to healthcare. L2S soon became a market leader in the life sciences in France and Europe. Five years after it was set up, in 2008, L2S was sold to Whitehead Mann, and Virginie Lleu became Senior Client Partner Life Sciences for Europe, supervising a team of some fifteen people.Drawing on her wide-ranging and significant experience and expertise developed at L2S, in October 2010 Virginie Lleu created the L3S Partnership, the aim being to become one of the leading executive search companies for the life sciences in Europe.

Microbiome & us
News
Dec 11, 2019
LNC Therapeutics and the National Institute for Agricultural Research (INRA) sign research partnership to study anti-...
> more
Nov 22, 2019
We are looking for preclinical project manager | WHAT WE OFFER An exciting opportunity to dive in and begin your career...
> more
Press / Media
Nov 12, 2019
Biotechs investments disrupt Big Pharma business model The pharmaceutical industry is in a state of flux, with...
> more
Sep 6, 2019
Chaque semaine, Maddyness dresse le bilan des levées de fonds de la semaine qui vient de s’écouler. Cette semaine,...
> more
Publications
Dec 6, 2019
The term “microbiome” refers to the collection of microorganisms (or microbiota) – including bacteria, viruses and...
> more
Oct 28, 2019
Jillian L. Waters, Ruth E. Ley The Christensenellaceae, a recently described family in the phylum Firmicutes, is emerging...
> more
now on twitter
LNC Therapeutics

Researchers demonstrated Lactobacillus rhamnosus can dose-dependently reestablish a balanced intestinal microbiome… t.co/QPFJhyzDrR

LNC Therapeutics © 2019 - all rights reserved terms and conditions